Sanofi announces ELIXA study results for Lyxumia (lixisenatide) cardiac outcomes study in type 2 diabetes patients
Sanofi announced the ELIXA (Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With Lixisenatide) study which showed that Lyxumia (lixisenatide) was non-inferior, although not superior, to placebo for cardiovascular safety. ELIXA full results will be presented Monday 8 June 2015, at the American Diabetes Association 75th Scientific Sessions in Boston by the ELIXA steering committee, chaired by Dr. Marc Pfeffer.
Comment: Lyxumia lasts longer and could have lower risks of hypoglycemia than Lantus (insulin glargine).The drug is approved in the EU and UK and Sanofi plans to resubmit Lyxumia to the FDA in the third quarter of 2015.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.